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Abstract
Purpose—It was recently reported that residential altitude is inversely associated with all-cause
mortality among incident dialysis patients; however, no adjustment was made for key case-mix
and laboratory variables. We re-examined this question in a contemporary patient database with
comprehensive clinical and laboratory data.
Methods—In a contemporary 8-year cohort of 144,892 maintenance dialysis patients from a
large dialysis organization, we examined the relationship between residential altitude and all-cause
mortality. Using data from the U.S. Geological Survey (USGS), the average residential altitudes
per approximately 43,000 U.S. zip codes were compiled and linked to the residential zip codes of
each patient.
Results—Mortality risks for these patients were estimated by Cox proportional hazard ratios
(HR). The study population's mean±SD age was 61±15 years, and patients included 45% women
and 57% diabetics. In fully-adjusted analysis, those residing in the highest altitude strata (≥6000
ft) had a lower all-cause mortality risk in fully-adjusted analyses: death HR: 0.92 (95% CI, 0.86–
0.99), as compared to patients in the reference group (<250 ft).
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Conclusions—Residential altitude is inversely associated in all-cause mortality risk in
maintenance dialysis patients notwithstanding the unknown and unmeasured confounders.
Keywords
Altitude; hypoxia; dialysis; mortality; environment
Introduction
It is known that living at higher altitudes can induce hypoxia related events. Because the
kidney is a key mediator of hypoxia-induced erythropoiesis,1 dialysis patients may be
especially susceptible to anemia under hypoxic conditions. Only one study has examined the
relationship between altitude and all-cause mortality in dialysis patients. This study, which
used 1995–2004 patient follow-up data from the United States Renal Data Survey (USRDS),
reported an inverse association between residential altitude and all-cause mortality in
incident dialysis patients.2 Relative to patients living at <76 m (250 ft), a 15% reduction in
mortality risk was seen in patients residing in the highest altitudinal strata (≥6000 ft). The
apparent reduction in mortality risk in ESRD patients at high altitudes was attributed largely
to the induction of hypoxia-induced factors, which may induce more effective
erythropoiesis3 and regulate enzymes associated with cardiovascular risk.4–6
A recognized limitation of this study, however, was the unavailability of several baseline
case-mix and laboratory variables that may strongly confound the altitude-mortality
relationship in maintenance dialysis patients. For instance, the analyses did not account for
markers of chronic inflammation or protein-energy malnutrition (PEM), which may
attenuate erythropoiesis7–10 and also diminish anemia responsiveness to EPO
administration.11, 12 Moreover, information on important modifiers of survival in dialysis
patients, such as access modality, was unavailable.
This study, with detailed information on patient malnutrition-inflammation complex
syndrome (MICS) status, as well as previously unavailable case-mix and laboratory
variables, will re-examine the altitude-mortality relationship in a contemporary cohort of
dialysis patients followed over 8 years (2001–2009). We hypothesize that higher residential
altitudes are associated with significantly different mortality risk among maintenance
dialysis patients.
Methods
Human Subjects and Data
All individuals with Stage 5 CKD who underwent dialysis treatment in one of the outpatient
dialysis facilities of a US based dialysis organization, i.e., DaVita, were eligible for entry
into the cohort from July 1, 2001 to June 30, 2006 and were followed for the outcome of
interest until June 30, 2009 for a total of 32 consecutive calendar quarters. The creation and
analyses of this non-concurrent, dynamic cohort of dialysis patients have been described
previously.13, 14 To minimize measurement variability and to address the effect of short-
term variation in dietary and fluid intake on weight or laboratory measurements, we
averaged all repeated measures for each patient during any given calendar quarter, i.e., over
13 consecutive weeks or 3 months. The study was approved by the Institutional Review
Committees of the Los Angeles Biomedical Research Institute at Harbor-UCLA and DaVita
Clinical Research. The requirement for a written consent form was waived because of the
large number and anonymity of the patients studied, and the non-intrusive nature of the
research.
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Dialysis Treatment
Dialysis vintage was defined as the duration of time between the first day of dialysis
treatment and the first day that the patient entered the cohort. The first (baseline) study
quarter for each patient was the calendar quarter in which patient's vintage was >45 days
during at least half of the time of that quarter. The administered dialysis dose was measured
by single-pooled Kt/V using urea kinetic modeling equations that are described elsewhere.15
Laboratory Values
Most blood samples were collected pre-dialysis with the exception of the post-dialysis
serum urea nitrogen, which was obtained to calculate urea kinetics. Blood samples were
drawn using uniform techniques in all dialysis clinics and were transported within 24 hours
to a single laboratory center (DaVita Laboratory in Deland, Florida), where the laboratory
values were measured by automated and standardized methods. Most laboratory values were
measured monthly, including serum creatinine, urea, albumin, calcium, phosphorus,
bicarbonate, alkaline phosphatase, and total iron-binding capacity (TIBC). Serum ferritin
and intact parathyroid hormone (PTH) were measured at least quarterly. Hemoglobin was
measured weekly to bi-weekly in most patients.
Integration of Altitude Data
Using data from the U.S. Geological Survey (USGS), the average residential altitudes of
approximately 43,000 U.S. zip codes were compiled and linked to the residential zip codes
of each DaVita patient.
Statistical Methods
Two analytical methods were used to assess the relationship between residential altitude and
all-cause mortality: 1) categorical hazard analyses, as described in our prior studies,2, 3 using
residential altitude stratified into five groups: <250 (reference), 250–<2000, 2000–<4000,
4000–<6000, and ≥6000 ft and 2) proportional-hazards regression models with restricted
cubic splines using continuous measurements of residential altitude, as used in similar
reports.14, 16 In the spline analyses, we used two degrees of freedom to generate one knot at
267 ft, corresponding to our second lowest altitudinal strata (250–<2000).
For each analysis, three models were examined based on the level of multivariate
adjustment: (a) an unadjusted model that included mortality as the outcome and entry
calendar quarter (q1 through q20) as covariates; (b) a case-mix adjusted model that included
the above plus age, sex, dialysis modality (hemodialysis vs. peritoneal), race/ethnicity
(African-Americans, non-Hispanic Caucasians, Asians, Hispanics, and Other), diabetes
mellitus, dialysis vintage, mode of access (arteriovenous fistula, graft, catheter, or other),
primary insurance, marital status, dialysis dose (single pool kt/v), erythropoietin dose, and
the following comorbidities: alcohol dependence, current smoker, atherosclerotic heart
disease, congestive heart failure, chronic obstructive pulmonary disorder, cerebrovascular
disease, peripheral vascular disease, and cancer; and (c) a MICS adjusted model which
included all of the covariates in the case-mix model as well as serum albumin, calcium,
bicarbonate, creatinine, ferritin, hemoglobin, lymphocyte, normalized protein nitrogen
appearance, phosphorus, white blood cell count, alkaline phosphatase, parathyroid hormone,
and body mass index.
We assessed variations in patient characteristics according to altitudinal strata by means of a
nonparametric test for trend across ordered groups. We also compared characteristics of the
highest altitude stratum (≥6000 ft) with those the reference group (<250 ft) with a t-test for
unequal variances (Table 1). With respect to our sample, patients who were transplanted or
left DaVita clinics were censored at the time of the event. We performed simple imputation
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for variable data that was unavailable, though missing data was less than 1% for most
laboratory and demographic variables. All analyses were carried out using Stata version 10.1
(Stata Corporation, College Station, Texas).
Results
The national cohort of the dialysis patients included 164,789 adult subjects. After excluding
patients who had missing ages or were <18 years of age (n=13,900); those who did not
maintain at least 45 days of thrice-weekly dialysis treatment during the base calendar quarter
(n=3,695); and those with a missing zip code linked residential altitude (n=2,302), our final
sample was comprised of 144,892 dialysis patients with a median follow-up time of 801
days. Table 1 shows the relevant demographic, clinical and laboratory data of these patients
according to 5 altitude categories. Approximately 50% of patients resided below 250 ft,
whereas 10% of patients lived at 1250 ft or above, and less than 1% at 6000 ft or above.
Patients in the highest altitudinal strata were more likely to be white, married, on peritoneal
dialysis and receive catheter dialysis access, as compared to patients in the lowest altitudinal
strata (<250 ft). These patients also had comparably higher hemoglobin and creatinine
levels, but lower parathyroid hormone (PTH) levels.
In Figure 1 and Table 2, we assessed the association between 5 categories of residential
altitude and 8 year all-cause mortality across 3 levels of adjustment. In case-mix adjusted
models, a protective effect was only observed in patients living at 4000 ft or greater, with
patients living in the highest altitudinal stratum (≥6000 ft) having a 10% lower mortality risk
relative to patients residing below 250 ft. Upon further adjustment for markers of
malnutrition and inflammation, there was only a minimal increase in the relative mortality
risk for patients living at ≥6000 ft (HR: 0.92 (95% CI, 0.86–0.99)); however, there was no
longer a significant protective effect for patients living between 4000–<6000 ft.
Figure 2 displays the association between continuous residential altitude and all-cause
mortality using restricted cubic spline models. In our unadjusted (Figure 2A) model, we
found a modest rise in mortality risk as residential altitude reached 2000 ft. Beyond this
point, mortality risk decreased substantially as altitude increased. After case-mix adjustment
(Figure 2B), the rise in mortality risk was only seen up to an altitude of 750 ft; thereafter,
mortality was also inversely associated with altitude. However, as noted with the decrease in
slope, the association of mortality with rising altitude was modestly attenuated after case-
mix adjustment. After further adjustment for MICS, (Figure 2C), an inverse trend for
mortality was observed throughout all levels of residential altitude, but was further
attenuated compared to the previous models and was only statistically significant between
2500 ft and 7500 ft.
Discussion
In a large cohort of dialysis patients within a U.S. based dialysis organization followed for
up to 8 years, we found that high residential altitude (≥6000 ft) is associated with a
significant reduction in all-cause mortality risk in dialysis patients. These results support
previous findings by Winkelmayer et. al. (HR: 0.85, 95% CI, 0.79–0.92 in dialysis patients
≥6000 ft relative to <250 ft)2, though the effect size we observed was smaller in comparison.
Notably, our fully-adjusted restricted cubic spline analysis (Figure 2c) depicted a fairly
different visualization of the altitude-mortality relationship as compared to the fully-adjusted
categorical hazard analyses (Figure 1). The spline model indicated statistically significant
reductions in mortality risk at approximately 2000 ft, while the categorical hazard model
indicated a statistically significant survival benefit only for patients residing at or above
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6000 ft relative to those below 250 ft, although patients one stratum lower (4000–<6000 ft)
also tended to have improved survival. We might account for these differences by
recognizing that when altitude is rendered as a continuous variable, low frequencies of
patients at various points of its domain may result in unstable instantaneous estimates of
mortality. The grouping effects of categorical hazard analysis, on the other hand, while
protective of unstable estimates, provide a weaker resolution of the altitude-mortality
relationship. That both analytical methods demonstrate a survival benefit associated with
high residential altitude (≥6000 ft), then, is reassuring, though spline model mortality
estimates were less stable beyond 7500 ft where patient sample size was low.
Previous reports attribute improved survival at high altitudes in dialysis patients to the
regulatory effects of hypoxia-induced factors on enzymes associated with cardiovascular
(CV) risk2, 17 such as heme oxygenase-1, inducible nitric oxide synthase, and VEGF.4–6
However, the activation of hypoxia-induced factors may be substantially influenced by
protein-energy malnutrition and chronic inflammation18, 19 conditions which are highly
prevalent in maintenance dialysis patients.20, 21 Moreover, chronic malnutrition and
inflammation may attenuate responsiveness to EPO administration in dialysis patients.11, 12
We found that most markers of malnutrition and inflammation (MICS) significantly
according to altitudinal strata. These differences might be accounted for, at least in part, by
1) variations in dietary habits according to patients’ geographical environments22 or 2) the
tendency of patients to migrate to lower altitudes during their lifetime according to their
health status.23 Contrary to our expectations, we observed that higher altitudes were
associated with lower creatinine levels, which may indicate reduced muscle mass and poorer
nutritional status in dialysis patients,24, 25 and hence would not explain the improved
survival in these altitudinal groups. While further studies are needed to explore the
paradoxical association between altitude and creatinine levels, adjustment for MICS
characteristics did not markedly influence survival trends among our cohort, suggesting the
patients’ composite inflammation and malnutrition status may not have varied meaningfully
as to differentially influence mortality.
Furthermore, while hypoxia-induced factor activation stimulates endogenous erythropoietin
in normal persons, this process is nearly absent in end-stage renal disease. Moreover,
dialysis patients are treated with exogenous erythropoietin to maintain serum hemoglobin
levels within KDOQI guidelines (≥11.0 g/dL but no greater than 13.0 g/dL26). Indeed,
serum hemoglobin levels varied only slightly (approximately 3%) by altitudinal strata in our
cohort. Because hypoxia-induced factors regulate a number of important biological
pathways beyond erythropoiesis that may influence mortality, including angiogenesis,
vascular remodeling, redox homeostasis, and energy metabolism,27–30 this lack of variation
in hemoglobin does not rule out hypoxia as a plausible mechanism for our observed results.
We also noted a “threshold” effect of altitude on mortality in our categorical hazard
analyses. Specifically, reductions in mortality became apparent only when residential
altitude reached 4000 ft or greater. One rationale for this observation pertains to hypoxia—
HIF-1α is an important oxygen-threshold sensor in humans,31, 32 but little is known about
the nature of this threshold. A number of studies cite 1500 meters (4921 ft) as the lower
limit for the onset of acute physiological hypoxic adaptations,31, 33–35 including the HIF-1α
dependent hypoxic ventilatory response31, 33, 36 hypoxic pulmonary vasoconstriction,33 and
stimulated erythropoiesis.34, 35 Moreover, in a study exploring the effects of acute hypobaric
hypoxia on endogenous EPO production, a simulated altitude of 2100m (~6890 foot) was a
threshold for sustained EPO release in healthy persons.31 While endogenous EPO
production is virtually absent in CKD patients, these findings may indicate a HIF-activation
threshold that may explain the reduced mortality we observed only at higher altitudes.
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The roles of hypoxia and anemia-independent pathways in the inverse altitude-mortality
association also merit consideration. For example, UV-B radiation exposure, which
increases 15% per 1000 meter (~3300 foot) rise in altitude, is an important source of vitamin
D,37 the latter of which has been associated with improved CV risk and all-cause mortality
in both healthy populations and incident dialysis patients.14, 38, 39 Although vitamin D data
was unavailable in this study, we found that patients residing in higher altitudinal strata
tended to have lower parathyroid hormone (PTH) levels, which may indicate improved
vitamin D status resulting from greater UV-B exposure at higher altitudes.40
Key strengths of our study include the use of a large contemporary and nationally
representative database with 8-years follow-up and the comprehensive availability of
clinical data allowing for adjustment of several important confounders such as nutritional
status, inflammation, preexisting co-morbidities, laboratory data, and erythropoietin dose.
However, several limitations of our study bear mention. Because our study is observational,
we are unable to definitively determine whether residential altitude itself influences all-
cause mortality. Furthermore, although we adjusted for a large number of covariates there is
always the possibility of residual confounding. We also lacked information on
measurements of Vitamin D levels and cause of death for this study, which may be
important in delineating the confounding effects of UV, and the contribution of
cardiovascular mortality, respectively, in future studies.
Conclusion
Our data confirm previous findings that high altitudes, in excess of 6000 ft, are associated
with a significant reduction in mortality risk. Further studies are needed to confirm our
findings, and to more clearly delineate the pathways by which high altitude confers a
reduction in mortality risk.
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Figure 1.
Association with residential altitude stratified into 5 levels (<250, 250–<2000, 2000–<4000,
4000–<6000, and ≥6000) with all-cause mortality in 144,892 dialysis patients.
Footnote: The Y-axis shows the logarithm of the hazard ratio of all-cause mortality over 8
years in. unadjusted, case-mix adjusted, and case-mix + MICS adjusted models. The
unadjusted model adjusts only for calendar quarter covariate. The case-mix model adjusts
additionally for age, sex, dialysis modality, race, diabetes, dialysis vintage, insurance,
marital status, dialysis dose, erythropoietin-α dose, and the following comorbidities: alcohol
dependence, smoking, atherosclerotic heart disease, congestive heart failure, chronic
obstructive pulmonary disorder, cerebrovascular disease, peripheral vascular disease, and
cancer. The case-mix + MICS model adjusts further for albumin, calcium, bicarbonate,
creatinine, ferritin, hemoglobin, lymphocyte, normalized protein nitrogen appearance,
phosphorus, white blood cell count, alkaline phosphatase, parathyroid hormone, and body
mass index. The reference group is dialysis patients residing below 250 feet.
Shapiro et al. Page 9
Hemodial Int. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
Association of average residential altitude with mortality in 144,892 dialysis patients over 8
years (7/2001–6/2009). Figure 2A represents unadjusted analyses, while figures 2B and 2C
represent case-mix adjusted analyses, and case-mix + MICS adjusted analyses, respectively.
Footnote: The Y-axis shows the logarithm of the hazard ratio of all-cause mortality over 8
years in. unadjusted, case-mix adjusted, and case-mix + MICS adjusted models. The
unadjusted model adjusts only for calendar quarter covariate. The case-mix model adjusts
additionally for age, sex, dialysis modality, race, diabetes, dialysis vintage, insurance,
marital status, dialysis dose, erythropoietin-α dose, and the following comorbidities: alcohol
dependence, smoking, atherosclerotic heart disease, congestive heart failure, chronic
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obstructive pulmonary disorder, cerebrovascular disease, peripheral vascular disease, and
cancer. The case-mix + MICS model adjusts further for albumin, calcium, bicarbonate,
creatinine, ferritin, hemoglobin, lymphocyte, normalized protein nitrogen appearance,
phosphorus, white blood cell count, alkaline phosphatase, parathyroid hormone, and body
mass index. Dashed lines represent 95% pointwise confidence bands.
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